Shares of EyePoint Pharmaceuticals EYPT were flat in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were up 45.00% year over year to ($0.11), which missed the estimate of ($0.10).
Revenue of $7,489,000 higher by 272.22% year over year, which beat the estimate of $7,250,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: May 06, 2020
Webcast URL: https://edge.media-server.com/mmc/p/wmbgnxa6
Technicals
52-week high: $2.69
52-week low: $0.70
Price action over last quarter: down 30.08%
Company Profile
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed 5 FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.